News

Excitement Builds at BEAMER Meeting in Düsseldorf as Model is Unveiled and Pilot Strategies are Developed 

Last month, members of the BEAMER project consortium gathered in Düsseldorf for the highly anticipated BEAMER Model Reveal and Pilot planning. The event marked a significant milestone, bringing together pilot teams and project partners to unveil the BEAMER model and strategize for the upcoming pilot implementations.
 

BEAMER Model Developments 

The excitement was high as the BEAMER Model was unveiled during this two-day meeting to project partners, promising to revolutionize patient care by enabling personalized, patient-centered support, which can enhance adherence. This innovative model is designed to segment patients into distinct groups based on their adherence behaviors and unique support needs, making it a game changer in the field of healthcare. 

Structured around four key layers, the BEAMER Model dives deep into the psychological and motivational factors that influence patient behavior. This enables healthcare professionals (HCPs) to gain a clearer understanding of what their patients truly need, empowering them to tailor support interventions and online patient support that resonate with individual experiences.  

Although the name and foundational details of the BEAMER Model were revealed to project partners, the anticipation is building as further insights into its structure and application are set to be shared in the coming month! The project team remains committed to refining the model, ensuring it is not only effective for patients but also easy for healthcare professionals to implement in real-world settings, paving the way for sustainable healthcare solutions. 

BEAMER Pilot Studies: Participant Recruitment and Criteria 

The pilot sessions during the recent two-day workshop in Düsseldorf provided an opportunity for developing and aligning strategies and protocols for the upcoming BEAMER pilot studies. Although not every partner was represented, those who attended shared valuable insights into the specific criteria and methodologies they will employ to identify and recruit research participants across a range of health conditions. 

 The following summary demonstrates the breadth of the validation planned: 

  • Servicio Madrileño de Salud (SERMAS)/FIIBAP: This group will focus on recruiting participants from primary healthcare centers, specifically targeting individuals with a high prevalence of cardiovascular diseases. This approach aims to capture relevant health data from those at significant risk, ensuring the study’s findings are both applicable and impactful.
     
  • Tilburg University (TiU): Participants will include individuals diagnosed with specific types of cancer at various stages of the disease. By involving patients across different stages, TiU aims to gather comprehensive data that reflects the diverse experiences and challenges faced by cancer patients.
     
  • Universitätsklinikum Düsseldorf (UDUS) (Head and Neck Cancer): Recruitment for this pilot will commence in December, focusing on patients with head and neck cancers who are often at risk due to factors such as alcohol use, nicotine consumption, and HPV exposure. Many of these participants also belong to lower-income groups, which highlights the importance of inclusivity in research. The follow-up period for this cohort will extend for at least six months.
     
  • Hospital Niño Jesús (SERMAS): This study will target teenagers aged 12 to 18 years with asthma. While there is potential to include younger children depending on ethical considerations, the focus remains on understanding the unique challenges faced by adolescent asthma patients.
     
  • Universitätsklinikum Düsseldorf (UDUS) (Chronic Rhinosinusitis): The second UDUS pilot will recruit patients suffering from chronic rhinosinusitis. This pilot aims to provide deeper insights into adherence patterns and management strategies for individuals dealing with long-term respiratory conditions.
     
  • Italian Multiple Sclerosis Foundation (FISM): Recruitment will focus on patients diagnosed with multiple sclerosis (MS) who are currently using disease-modifying drugs. The recruitment process is expected to span three months, ensuring a robust participant pool for the study.
     
  • APDP Diabetes Portugal (Type 2 Diabetes): This study will target patients with type 2 diabetes on insulin regimens, particularly those newly starting insulin or experiencing hypoglycemic events. To broaden their outreach, APDP will also utilize online recruitment strategies in addition to clinic-based approaches.
     
  • World Duchenne Organisation (WDO): The WDO pilot will recruit children with Duchenne and Becker muscular dystrophy, focusing on strategies to improve treatment adherence in pediatric care.
     
  • Universitätsklinikum Düsseldorf (UDUS) (Hereditary Angioedema): This final UDUS pilot will concentrate on individuals living with hereditary angioedema, a rare and chronic genetic disorder, aiming to understand their unique challenges and support needs.
     
  • MEDIDA: This pilot will recruit patients managing various chronic diseases, contributing to a broad understanding of adherence behavior across different conditions.
     

The unveiling of the BEAMER Model has sparked excitement across the consortium, and as the pilots move forward, more details about the model and its applications will be shared. This is a key moment for the BEAMER project, with pilots set to deliver valuable insights that will help transform patient support and adherence strategies across Europe.

Stay tuned for more updates on this announcement by following BEAMER on LinkedIn. 

Facebook
X
LinkedIn
Pinterest
Email
Threads
Print

We Would Be Happy to Hear Your Comments

Feel free to share your thoughts by contacting us

Contact Us

Supported by a grant from IMI, the project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA] and Link2Trials. The total budget is 11.9 M€ for a project duration of 60 months.

Disclaimer:
Information on this website reflects project owner’s views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

Follow us:

Youtube X-twitter Linkedin
Copyright 2024 © BEAMER PROJECT

Healthcare Professional

The primary aim of the end user personas is to support the creation of materials to support the implementation of the BEAMER model framework and to help define requirements for the elements of the BEAMER model framework. Hence, healthcare professionals (HCPs) represent the primary envisaged end user group of the BEAMER model framework and the associated Adherence Intelligence Visualisation Platform (AIVP)

It is one learning from the joint design process that the job titles of healthcare professional team members do not necessarily predict the roles they would play within the change management process for implementing BEAMER and installing it as a standard model within healthcare. Additionally, the role and responsibilities of certain job titles, for example nurse, varies across different healthcare systems and would affect how they interact with the BEAMER model outputs and the access they would be permitted and so it would not be helpful to include these job titles: The four personas represent role-independent archetypes within the group of HCPs. They encompass a Managerial HCP Persona, an Implementer HCP Persona, a Support HCP Persona, and a Established HCP Persona.

These healthcare professional personas may be further tailored to specific healthcare settings depending on the needs of the individual pilot sites. Thus, adapted or spin-off versions of these original personas may be considered. The persona displays include a summarising statement, goals, challenges, experience, and needs to enhance the accessibility and usability of the model while minimising user burden.

Close the popup

Patient Organisation

Patient organisations are considered potential users of the model outputs. Consequently, personas were designed for these groups to assure that the implementation materials may also support their needs in the longer term, thus fostering sustainability of the project outputs.

The identified focus areas within this persona are goals, needs, skills and tools, along with potential challenges anticipated during the implementation process. The persona emphasises awareness-raising, capacity building, education, peer support provision, and the promotion of research and development in therapeutic care.

The patient organisation persona serves as a theoretical framework representing how patient organisations could benefit from and include the BEAMER model framework in their therapy and care related as well as their organisational work. This persona comprises the needs, goals, challenges and necessary tools, facilitating preparation and implementation of the model and optimising the user experience of patient organisations as end users of the BEAMER model framework. It can be used as a guide to identify potential obstacles and understand the prerequisites for a patient organisation to successfully adopt and integrate the BEAMER model framework.

“In implementing the BEAMER model, we want to be able to respond to the different needs of our patients to ensure their adherence, build a supportive community and improve outcomes.”

Close the popup